This week was supposed to mark the end of composition pharmacies making the copying versions of Eli LillyZepbound weight loss drauter and his drug against Diabetes Mounjaro. Online, it does not seem that many things have changed.
Popular websites like Amble, Elliemd, Willow and Mochi Health are all shooting advertising versions, the active ingredient of Zepbound. Some, like IVIM, have stopped taking new patients.
Mochi Health does not intend to stop, and the four pharmacies he uses to provide drug patients, said CEO of Mochi Myra Ahmad. The company uses a network of around 500 suppliers to write prescriptions for weight loss drugs, including composed versions. It is to bet that the supply of personalized versions of drugs will prevent the company out of the reticle.
“These can be different dosage programs … Some patients prefer to increase much more slowly,” said Ahmad. “Some patients like to mix a number of other drugs in their compound formulations, depending on the side effects they have. Some patients have side effects with additives and brand name formulations. The composition really opens the door to such personalization.”
Amble, Elliemd and Willow did not respond to the request for CNBC comments.
The composition is the place where pharmacies mix the ingredients of a drug to create a specialized version for specific patients. Say that someone is allergic to a dye in a brand medication or needs a liquid form and that the main manufacturer only sells capsules. In this case, the patient can turn to a compound version.
When drugs are shortened, they can be aggravated in larger quantities to help fill the gap.
Copycat versions of Lilly’s Mounjaro and Zepbound and Novo NordiskWegovy and Ozempic have been widely available in recent years because the Food and Drug Administration of the United States has listed brand versions as lacking in non-them.
This created a booming company for pharmacies aggravating the very popular class of weight loss and diabetes called GLP-1.
But at the end of last year, the FDA said that all doses of Mounjaro and Zepbound were easily available and removed the drug from its shortage list, speaking the end of the mass of the drug. After months of judicial disputes, the FDA gave smaller pharmacies until the beginning of March to stop and larger pharmacies until this week before starting to apply its rules.
The largest facilities are no longer allowed to worsen the shooting. The little ones are not supposed to make products that are essentially copies of a trade available in the trade, a nickname with room for maneuver. The FDA considers essential copies such as those with a dosage at less than 10% of the drug available in the trade or combine two or more drugs available in the commercial.
Mochi insists that all of his prescriptions are personalized, including doses which differ from the standard forces of Zepbound. Other websites such as Elliemd advertise shooting mixed with vitamin B12.
Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said that formulations or dose forces that are not commercially available are not considered a copy. However, the combination of two drugs in one – such as adding vitamin B6 or B12 – would be considered a copy under strict reading of the FDA directives.
“FDA’s advice is quite clear about what is and is not a copy,” said Brunner. “And I would say that any pharmacy establishment or outsourcing of the composition which continues to prepare copies of the injection of shooting after putting itself today in a certain amount of legal risks.”
John Herr, pharmacist and owner of Town & Country Compounding Pharmacy, has stopped aggravating the shooting earlier this month. He did not want to take the risk even if his 300 to 400 patients have constantly called to complain about losing access.
Town & Country, based in Ramsey, New Jersey, invoiced patients about $ 200 per month – approximately a fifth the price of the list for Zepbound and less than half of the price that Lilly invoices to self -paying patients.
What is happening then is an open question. The application of the prohibition of the mass composition of the shooting fell mainly at the FDA. The agency did not immediately respond to the request for CNBC comments.
Lilly can try to pursue companies that continue, but it was not very lucky in the past. A Florida judge rejected one of Lilly’s affairs last year, saying that the company was trying to apply a law that only the FDA can.
Ahmad, the CEO of Mochi, said that she is not concerned about the action of Lilly against her providers. The way she sees it, they have established patient relationships with autonomy to decide the best way to manage their patients.
The next two months will be informative. According to the FDA, the mass composition of the semaglutide – the active ingredient of the Ozempic and the Wegovy of Novo Nordisk – must stop by the end of May, according to the FDA.
Hims & His Health already said that he would stop selling doses of semaglutide available commercially when the time comes. Customers who have a personalized dosage plan will be able to continue without any change, added the company.
-CNBC Leanne Miller contributed to this report